Calidi Biotherapeutics Inc. CLDI shares tumbled 35.04% in after-hours trading on Thursday to $0.50. The after-hours rally ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the pricing of its ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it intends to ...

Calidi Biotherapeutics Inc (NASDAQ:CLDI) shares are trading lower by 59% to $0.25 during Tuesday’s session after the company announced the pricing of a $6.1 million public offering. The offering ...

LOS ANGELES - March 11, 2025 (NEWMEDIAWIRE) - Calidi Biotherapeutics (NYSE American: CLDI) announced positive preclinical results for its systemic RTNova platform, demonstrating effective delivery of ...

Calidi Biotherapeutics Inc. Quarterly cash flow by MarketWatch. View CLDI net cash flow, operating cash flow, operating expenses and cash dividends.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...

herapeutics (NYSE American: CLDI) announced positive preclinical results for its systemic RTNova platform, demonstrating effective delivery of transient gene therapy payloads to targeted tumors. The ...